[New targets and new drugs in thoracic oncology].

  title={[New targets and new drugs in thoracic oncology].},
  author={Damien Rouvi{\`e}re and Emilie Bousquet and Elvire Pons and J D Milia and Nicolas M Guibert and Julien Mazi{\`e}res},
  journal={Revue des maladies respiratoires},
  volume={32 8},
A number of mechanisms that drive oncogenesis have been deciphered over the last 20 years. The main oncogenic factors in the field of thoracic oncology are mutations of EGFR, KRAS, and EML4-ALK translocation, which are most often reported in adenocarcinomas. However, new molecular targets have been highlighted recently including BRAF mutations, HER2 or PI3K, new translocations such as ROS1 or KIF5B-RET. Molecular abnormalities have also been identified in tumors other than adenocarcinoma… CONTINUE READING


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 63 references

Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts)

F Barlesi, M Beau-Faller, I Rouquette
J Clin Oncol 2013;31:A8000 • 2013
View 9 Excerpts
Highly Influenced

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2013
View 11 Excerpts
Highly Influenced

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 11 Excerpts
Highly Influenced

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015

Crizotinib in ROS 1rearranged non - small - cell lung cancer

AT Shaw, SH Ou, YJ Bang
N Engl J Med • 2014

Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial BRF113923

D Planchard, J Mazières, E Quoix
ESMO • 2014
View 2 Excerpts

Neratinib ( N ) with our without temsirolimus ( TEM ) in patients ( pts ) with non - small cell lung cancer ( NSCLC ) carrying HER 2 somatic mutations : An international randomized phase II study

B Besse, B Yao, M Kris
ESMO • 2014

Similar Papers

Loading similar papers…